Self-Limited Cytomegalovirus Infection During Natalizumab Treatment for Multiple Sclerosis.
| Autor: | Lima MR; Faculty of Medicine, University Center UNINTA, Sobral, Ceará, Brazil., Farias LABG; Faculty of Medicine, Federal University of Ceará (UFC), Fortaleza, Ceará, Brazil., da Ponte MF; Internal Medicine Department, Hospital Regional Norte (HRN), Sobral, Ceará, Brazil., de Arruda Furtado LET; Internal Medicine Department, Hospital Regional Norte (HRN), Sobral, Ceará, Brazil. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | European journal of case reports in internal medicine [Eur J Case Rep Intern Med] 2019 Feb 01; Vol. 6 (2), pp. 001046. Date of Electronic Publication: 2019 Feb 01 (Print Publication: 2019). |
| DOI: | 10.12890/2019_001046 |
| Abstrakt: | Natalizumab is indicated as monotherapy for the treatment of relapsing-remitting multiple sclerosis; it prevents outbreaks and delays the progression of physical disability. Here, we report the case of a 30-year-old patient with multiple sclerosis receiving natalizumab as monotherapy who subsequently developed self-limited cytomegalovirus disease. Cytomegalovirus infection has been reported during treatment with natalizumab, and in this study, we use new techniques to analyze the possible association of cytomegalovirus infection with natalizumab. Learning Points: Natalizumab is a humanized recombinant monoclonal antibody (IgG4k) against α4-integrin which promotes immunocompromise by blocking the adhesion interactions necessary for lymphocyte trafficking.Cytomegalovirus infection has been described during natalizumab treatment, although the pathogenesis and mechanisms are not complete understood.This case highlights the importance of awareness of this association and possible complications. Competing Interests: Conflicts of Interests: The Authors declare that there are no competing interests. |
| Databáze: | MEDLINE |
| Externí odkaz: |
|